 |
Management of Cardiovascular Risk Factors: Evidence-based Practice and Approaches CME Anthony C. DeFranco, MD, FACC; Steven P. Marso, MD, FACC; Adi E. Mehta, MD, FRCPC, FACE; Allen J. Taylor, MD, FACC, FAHA; David D. Waters, MD Author Information and Disclosures Release Date: April 23, 2008; Valid for credit through April 23, 2009 | Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians | | This CME activity is based on transcripts and slides of presentations as delivered by the faculty at multiple grand rounds programs during 2007.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME Activity - Management of Cardiovascular Risk Factors: Evidence-based Practice and ApproachesAnthony C. DeFranco, MD, FACC; Steven P. Marso, MD, FACC; Adi E. Mehta, MD, FRCPC, FACE; Allen J. Taylor, MD, FACC, FAHA; David D. Waters, MD
Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 XME |
|
|
Learning Objectives Upon completion of this activity, participants should be able to: - Explain the epidemiology of heart disease, relevant modifiable risk factors, and treatment approaches.
- Differentiate the biologic roles of both LDL-C and HDL-C
in terms of their impact on atherosclerotic burden.
- Describe the importance of HDL-C as an independent CV risk factor.
- Identify the cardiac imaging tools (ie, IVUS, CIMT) used to assess atherosclerotic burden and their clinical relevance in selecting and monitoring patients at risk for CV disease.
- Outline therapeutic approaches to the management of patients with multiple types of dyslipidemias.
Author Disclosures Anthony C. DeFranco, MD, FACC
Disclosure: Consultant: AstraZeneca, Pfizer Inc; Speakers’ Bureau: CV Therapeutics, Pfizer Inc
Steven P. Marso, MD, FACC
Disclosure: Grant/Research Support: American Diabetes
Association, Boston Scientific, Volcano Corporation; Consultant: Amylin, sanofi-aventis, Volcano Corporation
Adi E. Mehta, MD, FRCPC, FACE
Disclosure: Non-CME services received directly from a commercial interest or their agents: Amylin, Eli Lilly, GlaxoSmithKline, Merck, Novo Nordisk, Pfizer Inc, sanofi-aventis, Takeda
Allen J. Taylor, MD, FACC, FAHA
Disclosure: Grant/Research
Support: Kos Pharmaceuticals; Consultant: Kos Pharmaceuticals, Merck, Pfizer Inc
David D. Waters, MD
Disclosure: Consultant: Anthera, AtheroGenics, Eli Lilly, Pfizer Inc
|
 |
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME ®) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Excellence in Medical Education (XME). PIM is accredited by the ACCME to provide continuing medical education (CME) for physicians.
PIM designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
